Capecitabine is one of the drugs used as a first-line treatment in metastatic colorectal cancer, in combination with irinotecan, oxaliplatin, or the targeted agents bevacizumab and EGFR inhibitors (43, 44). The gene discussed is EGFR; the disease is metastatic colorectal cancer.